75472-37-6Relevant academic research and scientific papers
Biphenyl C-cyclopropylalkylamides: New scaffolds for targeting estrogen receptor β
Sarachine, Miranda J.,Janjic, Jelena M.,Wipf, Peter,Day, Billy W.
supporting information; experimental part, p. 2404 - 2408 (2010/01/16)
The C-cyclopropylalkylamide scaffold was previously identified as a new structural framework for antiestrogens. A second generation library provided three compounds that bind estrogen receptor (ER)α. Further screening of this library identified an ERβ hit
4,1-benzoxazepines, their analogues, and their use as somatostatin agonists
-
, (2008/06/13)
The present invention provides a compound of the formula: wherein ring A is an optionally substituted aromatic hydrocarbon ring or aromatic heterocyclic ring; ring B is an optionally substituted aromatic hydrocarbon ring or aromatic heterocyclic ring; Z is an optionally substituted cyclic group or linear hydrocarbon group; R1is a hydrogen atom, an optionally substituted hydrocarbon group or heterocyclic ring; R2is an optionally substituted amino group; D is a bond or an optionally substituted divalent hydrocarbon group; E is a bond, —CON(Ra)—, —N(Ra)CO—, —N(Rb)CON(Rc)—, —N(Rd)COO—, —N(Re)SO2—, —COO—, —N(Rf)—, —O—, —S— —SO—, —SO2—, (in which Ra, Rb, Rc, Rd, Reand Rfare respectively a hydrogen atom or an optionally substituted hydrocarbon group); G is a bond or an optionally divalent substituted hydrocarbon group; L is a divalent group; ring B may form an optionally substituted non-aromatic condensed nitrogen-containing heterocyclic ring by combining with R2; X is two hydrogen atoms, an oxygen atom or a sulfur atom;is a single bond or a double bond, and Y is a nitrogen atom whenis a double bond, or an oxygen atom, —N(R4)— (in which R4is a hydrogen atom, an optionally substituted hydrocarbon group or an acyl group) or S(O)n(in which n is 0, 1 or 2) whenis a single bond, or a salt thereof, which have somatostatin receptor agonistic action.
Heterocyclic compounds
-
, (2008/06/13)
Biphenylylquinuclidine derivatives of formula I, Q--Ar1 --Ar2, in which Q is of formula Ia or Ib, STR1 in which R1 and R2 are independently selected from hydrogen, alkyl, halogeno and hydroxy; or R1 and R2 when taken together define an oxo group; Xb is selected from --CH2 --, =CH-- and --CH(OH); Xa is selected from --CH2 --, =CH--, CO, --O--, and --S(O)n (wherein n=0, 1 or 2); Ar1 is a phenylene moiety; Ar2 is phenyl; and wherein one or both of Ar1 and Ar2 is optionally unsubstituted or substituted by one or more substituents independently selected from halogeno, hydroxy, amino, nitro, cyano, carboxy, carbamoyl, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, di-alkylamino, N-carbamoyl, N,N-di-alkylcarbamoyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, halogeno-alkyl, alkanoyl and alkanoylamino; and their pharamaceutically acceptable salts are inhibitors of squalene synthase and hence useful in treating diseases and medical conditions in which a lowering of cholesterol is desirable. The use of these derivatives in medicine is disclosed tohether with novel compounds, processes for their preparation and pharmaceutical composition containing them.
